2020 ESMO/EURACAN临床实践指南:肾上腺皮质癌和恶性嗜铬细胞瘤的诊断,治疗以及随访

2020-08-24 欧洲肿瘤内科学会 Ann Oncol . 2020 Aug 24;

2020年8月,欧洲肿瘤内科学会(ESMO)联合欧洲成人罕见实体瘤网(EURACAN)共同发布了肾上腺皮质癌和恶性嗜铬细胞瘤的诊断,治疗以及随访指南。指南主要内容涉及肾上腺皮质癌和恶性嗜铬细胞瘤的流行

中文标题:

2020 ESMO/EURACAN临床实践指南:肾上腺皮质癌和恶性嗜铬细胞瘤的诊断,治疗以及随访

英文标题:

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

发布机构:

欧洲肿瘤内科学会

发布日期:

2020-08-24

简要介绍:

2020年8月,欧洲肿瘤内科学会(ESMO)联合欧洲成人罕见实体瘤网(EURACAN)共同发布了肾上腺皮质癌和恶性嗜铬细胞瘤的诊断,治疗以及随访指南。指南主要内容涉及肾上腺皮质癌和恶性嗜铬细胞瘤的流行病学,分期和危险因素,局部病灶的管理,晚期和转移性疾病的管理,监测和随访。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=肾上腺皮质癌和恶性嗜铬.pdf)] GetToolGuiderByIdResponse(projectId=1, id=1b4df1c001968eec, title=2020 ESMO/EURACAN临床实践指南:肾上腺皮质癌和恶性嗜铬细胞瘤的诊断,治疗以及随访, enTitle=Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up, guiderFrom=Ann Oncol . 2020 Aug 24;, authorId=0, author=, summary=2020年8月,欧洲肿瘤内科学会(ESMO)联合欧洲成人罕见实体瘤网(EURACAN)共同发布了肾上腺皮质癌和恶性嗜铬细胞瘤的诊断,治疗以及随访指南。指南主要内容涉及肾上腺皮质癌和恶性嗜铬细胞瘤的流行, cover=https://img.medsci.cn/2020910/1599671809360_2020535.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology )是1975年成立的非盈利组织,是欧洲领先的专业组织,致力于提高肿瘤内科的专业性,推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Mon Aug 24 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年8月,欧洲肿瘤内科学会(ESMO)联合欧洲成人罕见实体瘤网(EURACAN)共同发布了肾上腺皮质癌和恶性嗜铬细胞瘤的诊断,治疗以及随访指南。指南主要内容涉及肾上腺皮质癌和恶性嗜铬细胞瘤的流行病学,分期和危险因素,局部病灶的管理,晚期和转移性疾病的管理,监测和随访。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=11634, tagName=嗜铬细胞瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=11634, guiderKeyword=嗜铬细胞瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4714, appHits=336, showAppHits=0, pcHits=1145, showPcHits=4378, likes=2, shares=13, comments=36, approvalStatus=1, publishedTime=Thu Sep 10 01:37:10 CST 2020, publishedTimeString=2020-08-24, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Sep 10 01:19:17 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 11:32:56 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=肾上腺皮质癌和恶性嗜铬.pdf)])
肾上腺皮质癌和恶性嗜铬.pdf
下载请点击:
评论区 (25)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1240018, encodeId=765a1240018e1, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07065554794, createdName=Karl24, createdTime=Sat Aug 20 20:00:57 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204244, encodeId=b60f1204244fa, content=!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6bc5505693, createdName=ms2000001010425621, createdTime=Sun Mar 20 08:46:19 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186115, encodeId=e3e811861159f, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6bc5505693, createdName=ms2000001010425621, createdTime=Wed Jan 19 19:05:33 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051269, encodeId=b5d1105126913, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a485472875, createdName=ms2000000982990246, createdTime=Tue Sep 14 21:09:27 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978665, encodeId=8e809e8665bc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b715537225, createdName=ms1000001942143464, createdTime=Thu Jul 01 16:42:04 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2022-08-20 Karl24

    学习一下

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1240018, encodeId=765a1240018e1, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07065554794, createdName=Karl24, createdTime=Sat Aug 20 20:00:57 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204244, encodeId=b60f1204244fa, content=!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6bc5505693, createdName=ms2000001010425621, createdTime=Sun Mar 20 08:46:19 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186115, encodeId=e3e811861159f, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6bc5505693, createdName=ms2000001010425621, createdTime=Wed Jan 19 19:05:33 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051269, encodeId=b5d1105126913, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a485472875, createdName=ms2000000982990246, createdTime=Tue Sep 14 21:09:27 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978665, encodeId=8e809e8665bc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b715537225, createdName=ms1000001942143464, createdTime=Thu Jul 01 16:42:04 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2022-03-20 ms2000001010425621

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1240018, encodeId=765a1240018e1, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07065554794, createdName=Karl24, createdTime=Sat Aug 20 20:00:57 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204244, encodeId=b60f1204244fa, content=!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6bc5505693, createdName=ms2000001010425621, createdTime=Sun Mar 20 08:46:19 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186115, encodeId=e3e811861159f, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6bc5505693, createdName=ms2000001010425621, createdTime=Wed Jan 19 19:05:33 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051269, encodeId=b5d1105126913, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a485472875, createdName=ms2000000982990246, createdTime=Tue Sep 14 21:09:27 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978665, encodeId=8e809e8665bc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b715537225, createdName=ms1000001942143464, createdTime=Thu Jul 01 16:42:04 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2022-01-19 ms2000001010425621

    学习了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1240018, encodeId=765a1240018e1, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07065554794, createdName=Karl24, createdTime=Sat Aug 20 20:00:57 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204244, encodeId=b60f1204244fa, content=!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6bc5505693, createdName=ms2000001010425621, createdTime=Sun Mar 20 08:46:19 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186115, encodeId=e3e811861159f, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6bc5505693, createdName=ms2000001010425621, createdTime=Wed Jan 19 19:05:33 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051269, encodeId=b5d1105126913, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a485472875, createdName=ms2000000982990246, createdTime=Tue Sep 14 21:09:27 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978665, encodeId=8e809e8665bc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b715537225, createdName=ms1000001942143464, createdTime=Thu Jul 01 16:42:04 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-09-14 ms2000000982990246

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1240018, encodeId=765a1240018e1, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07065554794, createdName=Karl24, createdTime=Sat Aug 20 20:00:57 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204244, encodeId=b60f1204244fa, content=!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6bc5505693, createdName=ms2000001010425621, createdTime=Sun Mar 20 08:46:19 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186115, encodeId=e3e811861159f, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6bc5505693, createdName=ms2000001010425621, createdTime=Wed Jan 19 19:05:33 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051269, encodeId=b5d1105126913, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a485472875, createdName=ms2000000982990246, createdTime=Tue Sep 14 21:09:27 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978665, encodeId=8e809e8665bc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b715537225, createdName=ms1000001942143464, createdTime=Thu Jul 01 16:42:04 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-07-01 ms1000001942143464

    很好

    0

拓展阅读

嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2016-04-02

嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2020-09-30

2021 国际共识:无症状SDHx基因突变携带者的初始筛查和随访

国外肿瘤科相关专家小组(统称) · 2021-05-21

《嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)》解读

福建医科大学附属第一医院全科医学科福建省高血压研究所 · 2021-08-15